Fresenius Medical Care stock faces November 3 results date

Published on 10/16/2026 at 15:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash flow hit EUR 860.00 million in the quarter. Fresenius Medical Care stock costs EUR 39.63 on October 16, 2026, up 0.43 percent versus the Xetra close.

Calendar And Cash Flow

The next quarterly results are scheduled for November 3, 2026.
Operating cash flow reached EUR 860.00 million in the second quarter of 2026.
Fresenius Medical Care stock costs EUR 39.63 at Lang & Schwarz on October 16, 2026 at 3:34 p.m. CEST, plus 0.43 percent versus the Xetra close of October 15, 2026.
Market capitalization stood at EUR 10.5 billion on October 16, 2026, with a price-to-earnings ratio of 11.92.

Aquarell-Illustration einer stilisierten Niere mit Wassertropfen in Blau- und Türkistönen — Eine zarte Aquarell-Illustration einer stilisierten menschlichen Niere mit Wassertropfen in Blau- und Türkistönen – symbolisch für die Kernkompetenz der Fresenius Medical Care AG (ISIN DE0005785802) in der Nierenersatztherapie, Illustration mit AI erstellt.

Fresenius Medical Care's next quarterly results are scheduled for November 3, 2026, according to the company's investor calendar. The stock was trading at EUR 39.63 at Lang & Schwarz on October 16, 2026 at 3:34 p.m. CEST, up 0.43 percent versus the Xetra close of October 15, 2026 at EUR 39.46.

Cash flow in the second quarter

Operating cash flow reached EUR 860.00 million in the second quarter of 2026, up 11.00 percent from EUR 775.00 million in the same quarter of 2025, according to Europe Says. The result gives the upcoming reporting date a concrete operating reference: cash generation improved even as the company manages network changes and investment needs.

Price sits inside yearly range

The Lang & Schwarz price stood EUR 4.09 above the 52-week low of EUR 34.57 and EUR 7.91 below the 52-week high of EUR 47.54, with the range dated October 16, 2026. That places the stock 16.63 percent below its yearly high and 14.64 percent above its yearly low. The bid was EUR 39.61 and the ask EUR 39.65 at the same timestamp.

Valuation and reporting date

Fresenius Medical Care had a market capitalization of EUR 10.5 billion and a price-to-earnings ratio of 11.92 on October 16, 2026. The November 3, 2026 results date is the next scheduled company event, while the investor calendar also lists the quarterly financial report for November 6, 2026.

Comparison with peers

FMC: plus 0.43 percent, price-to-earnings ratio 11.92, market capitalization EUR 10.5 billion
DaVita (NYSE, USD): plus 0.15 percent, price-to-earnings ratio 16.54, market capitalization USD 12.1 billion
Baxter International (NYSE, USD): plus 0.68 percent, price-to-earnings ratio minus 12.71, market capitalization USD 13.4 billion

Trading position and next date

For investors, the combination of a defined reporting date and stronger quarterly cash flow provides the clearest near-term framework. The valuation and yearly range add market context, while the daily move remains limited at 0.43 percent.

Fresenius Medical Care was trading at EUR 39.63 at Lang & Schwarz on October 16, 2026 at 3:34 p.m. CEST, plus 0.43 percent versus the Xetra close of October 15, 2026 at EUR 39.46. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.